Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation: Charting the future of pediatric IBD

Joseph A. Picoraro; Dale Lee; Caren A. Heller; Alandra Weaver; Jeffrey S. Hyams; Laurie S. Conklin; Anthony Otley; David Ziring; Subra Kugathasan; Joel R. Rosh; Andrew Mulberg; Lee A. Denson; Michael D. Kappelman; Andrew B. Grossman; Athos Bousvaros; K. T. Park

doi:10.1093/ibd/izy205

Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation: Charting the future of pediatric IBD

Joseph A. Picoraro
, Dale Lee
, Caren A. Heller
, Alandra Weaver
, Jeffrey S. Hyams
, Laurie S. Conklin
, Anthony Otley
, David Ziring
, Subra Kugathasan
, Joel R. Rosh
, Andrew Mulberg
, Lee A. Denson
, Michael D. Kappelman
, Andrew B. Grossman
, Athos Bousvaros
, K. T. Park

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The Crohn's & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.

Original language	English
Pages (from-to)	27-32
Number of pages	6
Journal	Inflammatory Bowel Diseases
Volume	25
Issue number	1
DOIs	https://doi.org/10.1093/ibd/izy205
State	Published - 1 Jan 2019
Externally published	Yes

Keywords

Crohn's disease
clinical trial
off-label use
pediatrics
ulcerative colitis

Access to Document

10.1093/ibd/izy205

Cite this

Picoraro, J. A., Lee, D., Heller, C. A., Weaver, A., Hyams, J. S., Conklin, L. S., Otley, A., Ziring, D., Kugathasan, S., Rosh, J. R., Mulberg, A., Denson, L. A., Kappelman, M. D., Grossman, A. B., Bousvaros, A., & Park, K. T. (2019). Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation: Charting the future of pediatric IBD. Inflammatory Bowel Diseases, 25(1), 27-32. https://doi.org/10.1093/ibd/izy205

@article{d5fc08e32c4a4924b69c74a87c532e67,

title = "Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation: Charting the future of pediatric IBD",

abstract = "The Crohn's \& Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's \& Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.",

keywords = "Crohn's disease, clinical trial, off-label use, pediatrics, ulcerative colitis",

author = "Picoraro, \{Joseph A.\} and Dale Lee and Heller, \{Caren A.\} and Alandra Weaver and Hyams, \{Jeffrey S.\} and Conklin, \{Laurie S.\} and Anthony Otley and David Ziring and Subra Kugathasan and Rosh, \{Joel R.\} and Andrew Mulberg and Denson, \{Lee A.\} and Kappelman, \{Michael D.\} and Grossman, \{Andrew B.\} and Athos Bousvaros and Park, \{K. T.\}",

year = "2019",

month = jan,

day = "1",

doi = "10.1093/ibd/izy205",

language = "English",

volume = "25",

pages = "27--32",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "Oxford University Press",

number = "1",

}

Picoraro, JA, Lee, D, Heller, CA, Weaver, A, Hyams, JS, Conklin, LS, Otley, A, Ziring, D, Kugathasan, S, Rosh, JR, Mulberg, A, Denson, LA, Kappelman, MD, Grossman, AB, Bousvaros, A & Park, KT 2019, 'Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation: Charting the future of pediatric IBD', Inflammatory Bowel Diseases, vol. 25, no. 1, pp. 27-32. https://doi.org/10.1093/ibd/izy205

TY - JOUR

T1 - Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation

T2 - Charting the future of pediatric IBD

AU - Picoraro, Joseph A.

AU - Lee, Dale

AU - Heller, Caren A.

AU - Weaver, Alandra

AU - Hyams, Jeffrey S.

AU - Conklin, Laurie S.

AU - Otley, Anthony

AU - Ziring, David

AU - Kugathasan, Subra

AU - Rosh, Joel R.

AU - Mulberg, Andrew

AU - Denson, Lee A.

AU - Kappelman, Michael D.

AU - Grossman, Andrew B.

AU - Bousvaros, Athos

AU - Park, K. T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The Crohn's & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.

AB - The Crohn's & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.

KW - Crohn's disease

KW - clinical trial

KW - off-label use

KW - pediatrics

KW - ulcerative colitis

UR - https://www.scopus.com/pages/publications/85058605494

U2 - 10.1093/ibd/izy205

DO - 10.1093/ibd/izy205

M3 - Article

C2 - 29931102

AN - SCOPUS:85058605494

SN - 1078-0998

VL - 25

SP - 27

EP - 32

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

IS - 1

ER -

Pediatric inflammatory bowel disease clinical innovations meeting of the Crohn's and colitis foundation: Charting the future of pediatric IBD

Abstract

Keywords

Access to Document

Fingerprint

Cite this